Mandated and Uniform Protocol for Conditions Included in Special Coverage

Initiation:

Any primary or specialist physician who have evaluated a patient may submit a request for Register subject to having available all required documentation for said condition. The insurer shall make a determination of approval or denial of registration and inform this decision in writing to the insured and the physician requesting the registration. If the physician requesting the registry is not the primary physician of the insured, the insurer shall send a copy of the determination to the primary care physician. The insurance company will make a final determination on the application for special coverage in a 72-hour period, after receiving the complete documentation as required by this Protocol for each condition.

Once a Provider supplies all the required information for the Contractor to process a registration and the Contractor processes such information, Special Coverage shall take effect retroactively as of the date the Provider reaches a diagnosis, including documentation of test results, for any condition included in Special Coverage. In case Information is submitted to the Contractor after the diagnosis was reached, coverage can be made retroactive up to sixty (60) Calendar Days before the date on which Provider submitted the registration request. (Contract Section 7.7.5)

Reactivation: Any insured who have lost eligibility for PSG for over one year period, will be required a new certification by the primary care physician that evidence current treatment plan to be reactivated in the special coverage. Any insured that loses its eligibility for a period less than 12 months, will be register without documents or additional certifications, unless there is any other limit for the specific condition.

Risk allocation*: the distribution of the special coverage between insurer and primary medical groups risk is defined in the following table. The same may be modify at the request of the insurance company subject to prior review and approval by ASES.

Notes:
1. Covered medications are those included in the pharmacy benefit and ASES drug formulary (FMC).
2. The codes or diagnoses by themselves do not grant inclusion into a temporary special condition list. They must be in compliance with the criteria for inclusion as specified in the column named: Criteria for inclusion in the coverage
<table>
<thead>
<tr>
<th>Special Condition</th>
<th>Definitive diagnosis criteria for inclusion in the coverage</th>
<th>Special Coverage Effectiveness and Duration</th>
<th>Services included in Special Coverage</th>
<th>Risk Allocation*</th>
</tr>
</thead>
</table>
| 1. Aplastic Anemia | 1-Diagnosis certification by a hematologist/oncologist with treatment plan  
2- Evidence of:  
   a. Absolute Neutrophils Count  
   b. Platelets Counts  
   c. Reticulocytes Counts  
   d. Results of bone Marrow aspiration or biopsy | **Effectiveness** = From the date of the diagnosis by the hematologist/oncologist or date the biopsy was performed if its reading establishes the definitive diagnosis.  
**Duration** = Special coverage will begin from the date the definitive diagnosis is established. Special cover will be in effect as long as the insured is eligible in the PSG | 1. All hospital services, emergency room or medical specialist services provided with primary diagnosis of Aplastic Anemia.  
2. All medical services provided or ordered by the hematologist/oncologist  
3. Medication prescribed by the oncologist/ hematologist and specific to treat the condition. | Insurer: Medical services and medications as defined for the special coverage condition in this document.  
GMP/PCP: Will receive the monthly capitation corresponding to the insured. |
| 2. Rheumatoid Arthritis | 1-Diagnosis certification by the rheumatologist in accordance with the criteria established by the American College of Rheumatology.  
(The insurance company will provide a sheet with the criteria and treatment plan to be fill by the specialist.)  
   a. American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) criteria | **Effectiveness** = From the date of the diagnosis by the rheumatologist.  
**Duration** = Special cover will be in effect as long as the insured is eligible in the PSG | 1. All hospital services, emergency room or medical specialist services provided with primary diagnosis of Rheumatoid Arthritis.  
2. All medical services provided or ordered by the rheumatologist.  
3. Medication prescribed by the rheumatologist and specific to treat the condition, including DMARD. | Insurer: Medical services and medications as defined for the special coverage condition in this document.  
GMP/PCP – Will receive the monthly capitation corresponding to the insured. |
1. Inflammatory arthritis affecting three or more joints.

2. Positive rheumatoid factor (RF) and/or anti-citrullinated peptide/protein (ACPA) functions, as evidence of anti-cyclic citrullinated peptide (anti-CCP) functions.

3. Elevated C-reactive protein or erythrocyte sedimentation rate.

4. Diseases with similar clinical features have been excluded, in particular psoriatic arthritis, acute viral polyarthritis, polyarticular gout or calcium pyrophosphate deposition disease, and systemic lupus erythematosus (SLE).

5. The duration of the symptoms is more than six weeks.

3. **Autism**
   
a. **Provisional Coverage**
   
a. Certification of risk by the primary care physician and evidence of the screening tool utilized.

<table>
<thead>
<tr>
<th>Provisional Special Coverage:</th>
<th>a. <strong>Effectiveness:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Diagnostic evaluation according to the Protocol of the Dept. of Health that includes family history, development and health,</td>
<td>a. Insurer – All services rendered by providers qualified for diagnostic evaluation.</td>
</tr>
</tbody>
</table>
### Codes to be used during the provisional coverage:

1. **R63.50** Unspecified lack of expected normal psychological development in childhood
2. **R62.0** Delayed Milestone in childhood
3. **F88** Other disorders of psychological development
4. **F80.2** Mixed receptive and expressive language disorders

### b. Permanent Special Coverage

#### b.1. Diagnosis certification by a clinical psychologist, school psychologist, counselor psychologist, neurologist, psychiatrist or a pediatrician development specialist.

Professionals should have training or experience in the area of Autism, as required by the Protocol of Autism from the Department of Health of PR.

#### b.2 Evidence of the relevant screening tests according to the Protocol of Autism from the Department of Health of PR.

#### b. Effectiveness:

From the date of the diagnosis certification by one of the listed professionals, the effective date will be the earliest certification date.

**Duration:** The provisional coverage will last for six months. If the evaluation process is not completed, the provisional coverage may be renewed for six additional months.

### GMP/PCP – Will receive the monthly capitation corresponding to the insured.

#### b. Medical services rendered or ordered by the psychiatrist, psychologist, neurologist, or any other qualified provider according to the Protocol of Autism from the Department of Health of PR will not require referral from the primary physician.

#### b. Insurer:

Medical services and medications as defined for the special coverage condition in this document.

**GMP/PCP – Will receive the monthly capitation corresponding to the insured.**

Department of Health, the primary care physician will complete the registration form for provisional special coverage and send it to the insurer. Once the provisional special coverage for autism is activate, a referral or authorization from the primary care physician to access the services of a qualified provider for the diagnostic evaluation process will not be required.

**Duration:** The provisional coverage will last for six months. If the evaluation process is not completed, the provisional coverage may be renewed for six additional months.

#### b.1. Diagnosis certification by a clinical psychologist, school psychologist, counselor psychologist, neurologist, psychiatrist or a pediatrician development specialist. Professionals should have training or experience in the area of Autism, as required by the Protocol of Autism from the Department of Health of PR.

#### b.2 Evidence of the relevant screening tests according to the Protocol of Autism from the Department of Health of PR.

#### b. Effectiveness:

From the date of the diagnosis certification by one of the listed professionals, the effective date will be the earliest certification date.

**Duration:** Special coverage will be valid, provided the insured eligibility to the PSG, until 21 years of age. After 21 years, to continue in the special coverage, a certification by a neurologist or psychiatrist establishing the need for the condition management and treatment as an adult is required.

Interview with tutors on the skills, behavior, communication and social interactions of the person, observation of the conduct of the person in interaction with others and own age play and socialization activities and the results of the most recent version of at least one instrument to document current behaviors.

**Interview with tutors on the skills, behavior, communication and social interactions of the person, observation of the conduct of the person in interaction with others and own age play and socialization activities and the results of the most recent version of at least one instrument to document current behaviors.**
<table>
<thead>
<tr>
<th>4. Cancer</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Diagnostic certification with stage, by a hematologist/oncologist or specialist physician in charge of the management of the condition, treatment plan with estimated start and completion dates. The insurer shall provide a specific form to be used as the Registry Application and Cancer Certification to be completed by the specialist.</td>
<td><strong>Effectiveness</strong> = from the date of certification of the diagnosis by the hematologist/oncologist or the biopsy date if its results establishes the definitive diagnosis.</td>
<td>1. All hospital services, emergency room or medical specialist services provided with primary diagnosis of Cancer.</td>
<td><strong>Insurer:</strong> Medical services and medications as defined for the special coverage condition in this document.</td>
</tr>
<tr>
<td>2-Evidence of diagnosis by biopsy result.</td>
<td><strong>Duration</strong> = until the end of active treatment of the condition with radiotherapy or chemotherapy. All insured will receive a certification of registration until the date in which the insured meets their surgical treatment, chemotherapy and/or radiation therapy. The insured will have the benefit of covered visits to his oncologist/hematologist to a maximum of one year. At the end of the year, if needed, the hematologist/oncologist may perform a request for extension of registration documenting the condition stage and the treatment plan for next year. A temporary register up to a maximum of 30 days shall be granted to receive documentation on the Cancer Registration Extension form provided by the insurer. If this process is not completed, the insured will automatically lose its registration for special coverage.</td>
<td>2-All medical services provided or ordered by the hematologist/oncologist.</td>
<td></td>
</tr>
<tr>
<td>3- In cases where the diagnosis cannot be confirmed by a pathology study, evidence of diagnostic studies of CT, MRI, PET Scan, ultrasonography supporting diagnosis or stage will be taken into consideration.</td>
<td>In cases of prostate cancer, treatment with hormonal chemotherapy will qualify the member to continue active in the cancer registry. Their visits to the urologist and medical orders and treatment ordered by this specialist (urologist) will be cover.</td>
<td>3- Medications prescribed by the hematologist/oncologist specific to treat the cancer condition.</td>
<td><strong>GMP/PCP</strong> — Will receive the monthly capitation corresponding to the insured.</td>
</tr>
</tbody>
</table>
In the cases of breast cancer, once active treatment with radiotherapy and chemotherapy ends, they will no longer remain in the registry. However, patients receiving treatment with anti-estrogens will continue being considered under cancer special coverage.

5. Skin Cancer: Carcinoma In Situ

- Positive Biopsy Report

**Effectiveness:** Special coverage in skin cancer and carcinoma in situ will only apply to the surgery day.

**Duration:** the day or days for surgical removal and all services on said day and any other radiotherapy treatment used any time.

Surgical removal and all related services on said day and any other subsequent radiotherapy/chemotherapy treatment.

**Insurer:**
Medical services and medications as defined for the special coverage condition in this document.

GMP/PCP: Will receive the monthly capitation corresponding to the insured.

6. Skin Cancer such as Invasive Melanoma or squamous cells with evidence of metastasis.

- Positive biopsy or pathology
  - Special studies like CT Scan, MRI, Sonogram
  - Registry certification completed by a dermatologist or a hematologist/oncologist.

**Effectiveness:** From the date the diagnosis is established.

**Duration** = until the end of the active treatment of the condition with radiotherapy or chemotherapy. All insured will receive a certification of registration for up to a year. At the end of the year, if needed, the dermatologist or hematologist/oncologist may request an extension of registration documenting the condition stage and the treatment plan for the next year. A temporary register up to a maximum of 30 days shall be granted to receive documentation on the Cancer Registration Extension form provided by the insurer. If this process is not

1. All hospital services, emergency room or medical specialist services provided with primary diagnosis of indicated Skin Cancer.
2-All medical services provided or ordered by the dermatologist or hematologist/oncologist.
3- Medications prescribed by the dermatologist or hematologist/oncologist specific to treat the cancer condition.

**Insurer:**
Medical services and medications as defined for the special coverage condition in this document.

GMP/PCP: Will receive the monthly capitation corresponding to the insured.
<table>
<thead>
<tr>
<th>Level 1 and 2</th>
<th>Level 3 and 4</th>
<th>Level 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1: GFR over 90, ICD-10-N18.1</td>
<td>Level 1 and 2: Does not qualify for registry under special coverage.</td>
<td>GMP/PCP: Levels 1 and 2 are total risk of GMP.</td>
</tr>
<tr>
<td>Level 2: GFR between 60 to 89, ICD-10-N18.2</td>
<td>Level 3 and 4: Qualifies for special coverage registry.</td>
<td>Level 3 and 4: The insurer assumes the nephrologist visits (without referrals), renal laboratory and diagnostic studies ordered by this specialist, peripheral vascular studies to document hemodialysis access and drugs ordered by the nephrologist, related to the condition and limited to immunosuppressants, erythropoiesis stimulants, Megace, renal antidotes and systemic corticosteroids.</td>
</tr>
<tr>
<td>Level 3: GFR between 30 to 59, ICD-10-N18.3</td>
<td>Effectiveness: From the date the diagnosis is established.</td>
<td>GMP/PCP: Levels 1 and 2 are total risk of GMP.</td>
</tr>
<tr>
<td>Note: Starting on October 2020 the ICD-10 Codes for CKD3 will change. N18.0 will no longer be used. Subcategories of CKD3 will be identified as follows: *N18.30 Chronic kidney disease, stage 3 unspecified</td>
<td>Duration = As long as the insured is eligible in the PSG.</td>
<td>Level 3 and 4: Insurer: All medical services provided or ordered by nephrologist from the date of effectiveness of the coverage. Additionally including: - insertion of catheters for dialysis - surgeries for arteriovenous (AV) fistulas - Administration of hematopoietic agents - blood transfusions</td>
</tr>
<tr>
<td>Level 4: GFR between 15 to 29, ICD-10-N18.4</td>
<td>GMP/PCP</td>
<td>GMP/PCP Level 3 and 4:</td>
</tr>
<tr>
<td></td>
<td>Level 3 and 4: All services covered by the PSG as long as the insured is active in the Special Coverage Registry.</td>
<td>Will receive the monthly capitation corresponding to the insured.</td>
</tr>
<tr>
<td></td>
<td>Level 5:</td>
<td>Level 5: Insurer: Once the registration for chronic kidney condition is</td>
</tr>
<tr>
<td></td>
<td></td>
<td>completed, the insured will automatically lose its registration for special coverage.</td>
</tr>
</tbody>
</table>
| Level 5: GFR less than 15  
ICD-10-N18.5  
ICD-10-N18.6 (ESRD) | **Effectiveness:** From the date the diagnosis is established.  
**Duration** = As long as the insured is eligible in the PSG | authorized, the insured received a notice by mail, indicating the changes in the coverage or the change of the GMP to one of the Renal-GMP (Dialysis Center). The change of GMP will be effective the month in which the change request is done. From this moment, the monthly capitation to the GMP for this insured is discontinued. The risk of the services received by the insured prior to the exchange of GMP or registration of the insured will be at the risk of the GMP, except those dealing directly with dialysis. Outpatient services, except emergency, provided to the insured in the Renal GMP have to be coordinated by the nephrologist, who will become the primary physician of the insured.  
**GMP/PCP:**  
**Level 5** – Will not receive monthly capitation for the insured. |
|---|---|---|
| **8. Scleroderma** | 1. Diagnosis certification by the rheumatologist including signs and symptoms supporting the diagnosis.  
2. Evidence of a positive ANA Test > or equal to1:80 dil | **Effectiveness:** From the diagnosis certification date by the rheumatologist.  
**Duration** = As long as the insured is eligible in the PSG |
<p>| | 1. All hospital services, emergency room or medical specialist services provided with primary diagnosis of Scleroderma. | <strong>Insurer:</strong> Medical services and medications as defined for the special coverage condition in this document. |</p>
<table>
<thead>
<tr>
<th></th>
<th>Positive skin biopsy</th>
<th>Effectiveness: From the date a definitive diagnosis is certified, and a treatment plan is established by the neurologist.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3. Positive skin biopsy</td>
<td>Duration = As long as the insured is eligible in the PSG</td>
</tr>
<tr>
<td></td>
<td>The insurer will develop a Registry form for this condition to be completed by the specialist certifying the condition, the criteria used to establish the diagnosis and the treatment plan.</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>All medical services provided or ordered by the rheumatologist.</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Medication prescribed by the rheumatologist and specific to treat the condition.</td>
<td></td>
</tr>
<tr>
<td>GMP/PCP:</td>
<td>Will receive the monthly capitation corresponding to the insured.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Multiple Sclerosis (MS) and Amiotrophic Lateral Sclerosis (ALS)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Certification of the diagnosis by a neurologist confirming condition and plan of treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Evidence of relevant diagnostic studies performed to reach diagnosis such as: MRIs, EMG, Evoked potentials, NCS, lumbar puncture, Genetic studies, etc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Effectiveness: From the date a definitive diagnosis is certified, and a treatment plan is established by the neurologist.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Duration = As long as the insured is eligible in the PSG</td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>All hospital services, emergency room or medical specialist services provided with primary diagnosis of MS or ALS.</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>All medical services provided or ordered by the neurologist.</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Medication prescribed by the neurologist and specific to treat the condition.</td>
<td></td>
</tr>
<tr>
<td>Insurer:</td>
<td>Medical services and medications as defined for the special coverage condition in this document.</td>
<td></td>
</tr>
<tr>
<td>GMP/PCP:</td>
<td>Will receive the monthly capitation corresponding to the insured.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Cystic Fibrosis</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Sweat test</td>
<td>Effectiveness: From the date a definitive diagnosis is certified, and a treatment plan is established by the pneumologist.</td>
</tr>
<tr>
<td></td>
<td>2. Evidence of treatments</td>
<td>Duration = As long as the insured is eligible in the PSG</td>
</tr>
<tr>
<td></td>
<td>3. Diagnosis certification by a pneumologist.</td>
<td>All services covered by the PSG as long as the insured is active in the Special Coverage Registry.</td>
</tr>
<tr>
<td>Insurer:</td>
<td>All medically necessary services cover by the PSG.</td>
<td></td>
</tr>
<tr>
<td>GMP/PCP:</td>
<td>Monthly capitation does not apply for this insured.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Hemophilia</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>11.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Certification of diagnosis by a hematologist</td>
<td>Effectiveness: From the date a definitive diagnosis is certified, and a treatment plan is established by a hematologist.</td>
</tr>
<tr>
<td></td>
<td>2. Evidence of relevant studies and test</td>
<td>Duration = As long as the insured is eligible in the PSG</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1- All hospital services, emergency room or medical specialist services provided with a diagnosis of hemophilia.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2-All medical services provided by the hematologist.</td>
</tr>
<tr>
<td>Insurer:</td>
<td>Medical services and medications as defined for the special coverage condition in this document.</td>
<td></td>
</tr>
<tr>
<td>GMP/PCP:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### 12. Leprosy

- 1. Evidence of skin biopsy result
- 2. Infection positive cultures
- 3. Diagnosis certification by an infectologist or a dermatologist.

**Effectiveness** = starts from the date of certification, which establishes the definitive diagnosis by the infectious disease specialist or a dermatologist.

**Duration** = It ends when the treatment is complete.

- 1. All hospital services, emergency room or specialist, cultures, and biopsies of follow-up, provided with a diagnosis of leprosy. (ICD-10 A30)
- 2. All medical services provided by the infectious disease specialist or dermatologist.
- 3. Medications prescribed by the infectious disease specialist or dermatologist.

**Insurer:** Medical services and medications as defined for the special coverage condition in this document.

**GMP/PCP:** Will receive the monthly capitation corresponding to the insured.

### 13. Systemic Lupus Erythematosus (SLE)

- 1. Diagnosis certification by a rheumatologist with evidence of the following tests: ANA Test, DS-DNA, Anti Sm y Anti Phospholipids.

**Effectiveness** = from the date of certification establishing the definitive diagnosis by the rheumatologist

**Duration** = As long as the insured is eligible in the PSG.

- 1. All hospital services, emergency room or medical specialist services provided with primary diagnosis of SLE.
- 2. All medical services provided or ordered by the rheumatologist.
- 3. Medication prescribed by the rheumatologist and specific to treat the condition of SLE.

**Insurer:** Medical services and medications as defined for the special coverage condition in this document.

**GMP/PCP:** Will receive the monthly capitation corresponding to the insured.
<table>
<thead>
<tr>
<th><strong>14. Children with Special Health Needs</strong></th>
<th>Complete the Registration Form for children with special health care needs by the primary care physician with evidence of the condition according to the list of diagnoses included by ASES as an attachment to the contract, entitled &quot;Conditions to include patients in the Register of Children with Special Health Needs&quot;, revision of June 2015. Medical evidence will consist of relevant laboratories or tests, evidence of current treatment, diagnosis certifications by specialist physicians consulted and others.</th>
<th><strong>Effectiveness</strong>: From the diagnosis certification date</th>
<th>As defined in the Conditions List revised on June 2015.</th>
<th>Refer to the listing of diagnosis codes of the conditions for Children with Special Needs Registry.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>15. Obstetric</strong></td>
<td>Obstetric Registry Form Certification of pregnancy by the obstetric gynecologist</td>
<td><strong>Effectiveness</strong>: After registration, a certification of the special coverage will be mail to the insured.</td>
<td>All services covered by the PSG as long as the insured is active in the Special Coverage Registry.</td>
<td>Insurer: All cover medical services and medications as long as the insured is active under this special coverage category.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Duration</strong>: Registration will be effective since the estimated day of conception according to certification provided by the obstetrician and will continue to be effective until 56 days after the delivery date, provided this occur after the 20th week. If pregnancy ends in miscarriage before week 20, will only granted 30 days after the event.</td>
<td><strong>Sterilization</strong>: Sterilization carried out in a separate admission, after childbirth or caesarean section, will be responsibility of the primary medical group, therefore it will require referral from the PCP</td>
<td>GMP/PCP: Will not receive monthly capitation for the insured.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Newborn</strong>: newborn children will be cover as long as the mother have eligibility for the PSG, and until the Obstetrics Registration in effect (56 days of the date of birth) at risk of the insurance company.</td>
<td><strong>Newborn</strong>: per capita payment shall be paid for the newborn once the mother is out of the registration or the newborn is certified by the mother, whichever occurs first.</td>
</tr>
</tbody>
</table>
**16. Tuberculosis (Tb)**

| Pneumologist Certification with treatment plan and evidence of: |
|---|---|---|---|
| 1- Tb test result |
| 2- Chest radiology findings |
| 3- Samples of sputum or bronchial wash for Acid-Fast Basillus (AFB) and culture for Mycobacterium tuberculosis. |
| 4- Biopsies of the affected area, if applicable. |
| 5- HIV test results |

**Effectiveness** = from the date of certification establishing the definitive diagnosis by the pneumologist.

**Duration**: Coverage will be variable, depending on the duration of the treatment, which can fluctuate between six (6) months to (1) year, depending on the plan of treatment certified by the pulmonologist. After the first year, if the patient requires continuing treatment, a re-evaluation of the case by the pulmonologist will be requested and according to the new plan of treatment, special coverage may be extended.

- Medical services related to the condition, follow-up, complications, complications of the diagnostic procedure and treatment shall be at the risk of the insurer from the date of effectiveness of the special coverage.
- Special coverage includes medications to treat or control the special condition or conditions that may arise as part of diagnostic studies performed or from complications of the disease.
- Chest radiology for follow up until the treatment is completed will be responsibility of the insurer.

**Department of Health of PR covers:**
- Tuberculin
- Culture
- Bronchial washing
- Medical treatment

**Insurer:**
Medical services and medications as defined for the special coverage condition in this document.

**GMP/PCP:**
Will receive the monthly capitation corresponding to the insured.
| 17. HIV/AIDS | Evidence of the result of any of the following laboratories;  
1- Western Blot positive  
2- positive HIV Viral load  
3- positive 4th generation test with validation of the subtypes of antibody or Antigen for acute infection.  
The registration may be requested by one of the following providers:  
- Primary Care Physician  
- HIV/AIDS Clinics Physician  
- VIH/AIDS Clinics Case Manager | **Effectiveness** = from the date of certification establishing the definitive diagnosis  
**Duration** = As long as the insured is eligible in the PSG | 1. All hospital services, emergency room or medical specialist services provided with primary diagnosis of HIV/AIDS.  
2. All medical services provided or ordered by HIV/AID treaters.  
3. Medications prescribed by the HIV/AID treaters specific to treat the HIV/AID condition. | Insurer:  
Medical services and medications as defined for the special coverage condition in this document.  
**GMP/PCP** – Will receive the monthly capitation corresponding to the insured. |
|---|---|---|---|---|
| 18. **Adults with phenylketonuria (PKU)** | When the special coverage is a continuation to the coverage under children with special conditions, once the beneficiary reaches age 21, no additional evidence is required. The evidence that qualifies he/she as a child, serves the purpose for the continuation of coverage under the category of adult PKU.  
If it is not a continuation of coverage, the registry has to be request by the geneticist and shall include a treatment history and evidence of the result of the genetic study. | **Effectiveness:** it is a continuation of the registry under children with special conditions, after the beneficiary reaches age 21.  
**Duration** = As long as the insured is eligible in the PSG | 1. All hospital services, emergency room or medical specialist services provided with primary diagnosis of PKU.  
2. All medical services provided or ordered by the geneticist.  
3. Medication prescribed by the geneticist and specific to treat the condition of PKU. | Insurer:  
Medical services and medications as defined for the special coverage condition in this document.  
**GMP/PCP:** Will receive the monthly capitation corresponding to the insured. |
| 19. Pulmonary Hypertension | Diagnosis certification and treatment plan by the Pneumologist or Cardiologist and evidence of supporting test(s). | **Effectiveness** = from the date of certification establishing the definitive diagnosis by the pneumologist or cardiologist.  
**Duration** = As long as the insured is eligible in the PSG | 1. All hospital services, emergency room or medical specialist services provided with primary diagnosis of Pulmonary Hypertension or its complications.  
2. All medical services provided or ordered by the pneumologist or cardiologist to treat the condition or its complications.  
3. Medication prescribed by pneumologist or cardiologist to treat the condition or its complications. | Insurer:  
Medical services and medications as defined for the special coverage condition in this document.  
GMP/PCP:  
Will receive the monthly capitation corresponding to the insured. |
|---|---|---|---|---|
| 20. Post-Transplant | The primary care physician or the specialist (nephrologist, pneumologist, cardiologist, hepatologist or gastroenterologist) must submit:  
- A certification of the post transplant status including the diagnosis and transplant date  
- Treatment plan with starting dates  
- Specific immunosuppressors, doses and route of administration. | **Effectiveness** = from the date of certification and treatment plan  
**Duration**: Special cover will be in effect as long as the insured is eligible in the PSG | 1. All hospital services, emergency room or medical specialist services provided related to the primary condition of post-transplant or its complications.  
2. All medical services provided or ordered by the specialist or primary care physician to treat the post-transplant condition or its complications.  
3. Medication prescribed by the specialists or primary care physician to treat the post-transplant condition or its complications. | Insurer- All medically necessary services cover by the PSG.  
GMP/PCP: Will receive the monthly capitation corresponding to the insured. |
| 21. HCV (Chronic Hepatitis C) | For its registry will be necessary to submit diagnosis certification including evidence of the following: | **Effectiveness**: From the date of registration with required certification and test results. | 1. Direct access to the specialist or subspecialist that handles condition without referral of the PCP.  
2. Treatment with the direct-acting antiviral drug (DDA) as established | Insurer- Medical services as defined for the special coverage condition in this document. Including but not limited to: Laboratories, (CMP,
| **diagnosed with Chronic Hepatitis-C under the GHIP” and to CN 20-0326)** | • Positive result for HCV antibody (Ab) test and  
• Positive Quantitative RNA test  
• Treating physician should document and submit the treatment plan with estimated start and completion dates.  
• Treating physician should include in the registry, documents of letter of willingness to be treated from the beneficiary and agreements to start treatment immediately upon Registry in Special Condition Registry. |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Duration</strong></td>
<td><strong>Duration</strong> HCV special coverage will be in effect since the time the patient is registered on this special coverage until six (6) months after completing treatment with the direct-acting antiviral drug (DDA) with evidence of sustained virological response not detected. If after six (6) months after completion of treatment, there is no evidence of sustained virologic response, then the Gastroenterologist or treating physician MUST document next step of management and treatment with specific start and completion dates. Otherwise the Beneficiary will revert to regular coverage and will be discontinued from special registry and coverage.</td>
</tr>
<tr>
<td><strong>under the Coverage of medication of ASES without countersignature of the PCP.</strong></td>
<td><strong>under the Coverage of medication of ASES without countersignature of the PCP.</strong> 3. Medically Necessary Laboratories for the condition without referral of the PCP. 4. Imaging, sonography, MRI, CT or any other radiological imaging medically necessary for the condition without referral of the PCP.</td>
</tr>
<tr>
<td><strong>PT &amp; INR, CBC, Renal function test’s, genotype, RNA quantitative, resistant test as needed, radiological imagines (sonogram, =with and w/o elastography, Liver CT and MRI if clinically indicated)and or any other medically necessary laboratories or tests to identify gradation and estimated degree of liver fibrosis in Hepatitis C, including liver biopsy with or w/o imaging guidance, &amp; pathology report. Also included are the visits to Gastroenterologist or other specialized authorized physician as described in the “Policy for the management of patients diagnosed with Chronic Hepatitis-C under the GHIP” Laboratories, tests, imaging studies and interventional radiologist evaluation, biopsy and pathological report are covered from the moment the patient is included in the special coverage and until discharged from the special coverage inclusion. The recommended follow up during the medical treatment is included in the “Policy for the management of patients diagnosed with Chronic</strong></td>
<td></td>
</tr>
</tbody>
</table>
Hepatitis-C under the GHIP® as guidelines. (see pages 22-23).

**GMP/PCP**: Will receive the monthly capitation corresponding to the insured.

**ASES**: Pharmacological treatment with direct-acting antiviral drug (DDA).
### Congestive Heart Failure (CHF): Class III and Class IV, NYHA.

**ICD 10 Codes:**
- I50 Heart failure
- I50.1 Left ventricular failure, unspecified
- I50.2 Systolic (congestive) heart failure
- I50.20 Unspecified systolic (congestive) heart failure
- I50.22 Chronic systolic (congestive) heart failure
- I50.84 End stage heart failure

The treating cardiologist must fill a certificate stating the diagnosis of CHF with reduced Ejection Fraction (HFrEF) and document an Ejection Fraction (EF) equal or less than 30% and report with objective evidence findings and treatment offered to the beneficiary so far, until the date of referral. Must state that the Beneficiary is a real candidate for heart transplant and document at least one (1) of the followings:
1. Left Ventricular Ejection Fraction (LVEF) equal or less than 30%.
2. Recurrent or frequent hospitalizations because of decompensated Heart Failure.
3. Symptomatic CHF despite optimization of available medications and or the use of medical devices for treatment or compensation of CHF. (LVAD) or Left Ventricular Assist Devices.
4. Continued and prolonged large doses of, or frequent increase in, dosages of diuretic medications.
5. Dependant on positive inotropics medications.

**AND:**
- Absence of severe right ventricular dysfunction and tricuspid regurgitation.

**Effective date of inclusion:**
Special Temporary Coverage as special condition will be effective when all the documentation in the second column is submitted by the treating cardiologist and is preliminary evaluated and accepted by the Transplant Center for further evaluation as a potential or possible candidate for heart transplant.

**Duration of Coverage:**
This Special Temporary Coverage will last only for a MAXIMUM non-extendable period of four (4) months, commencing on the effective inclusion date, and will last for four months or until the Beneficiary is accepted for transplant or declined as a candidate for transplant whichever occurs first. After this timeframe, the beneficiary will return to the Regular Coverage without any further appeal.

The following tests, laboratory tests or work up will be covered only ONCE during the Special Temporary Coverage Period:
- ABO type and Screen
- CBC + differential
- Glycosylated Hgb
- Lymphocyte Sub- Population Determination
- CMP
- TSH, T3, T4
- Uric Acid blood levels.
- Fasting Lipid Profile
- Urinalysis, Urine Culture
- Blood and Throat culture X1.
- Urine Collection X 24 hrs. for creatinine clearance and total proteins
- CMV
- Toxoplasma
- Varicella
- Herpes Simplex
- Measles
- Rubella
- Epstein Bar IgG & IgM
- HIV
- Hepatitis profile
- RPR
- Legionella Antibodies
- Panel Reactive Antibodies
- HLA A, B, DQ, DR
- Nicotine in urine
- Stool for OVA and Parasites
- Stool for Occult Blood in patients 50 years old or older.
- Pregnancy Test in female in reproductive age.
- PSA (males > 40 años)

**MCO:**
At risk of all studies, laboratories, and medical and other included evaluations according to the list in the left column during the period of four (4) months as described in column three.

**GMP/PCP:**
Will receive his monthly capitation during the special temporary coverage period. All studies, laboratory and medical evaluations will be given back to the Beneficiary and be available in electronic format to the treating cardiologist and PCP. All these evaluations will count toward quality requirements for PCP evaluations and CMO incentives as contracted with PCP.
The following evaluation will be covered:

To minimize duplication of services and studies, the evaluations will be done after all the laboratory results pertinent to the specialist who will evaluate the Beneficiary are available:

- Neumologist
- Neprologist
- Infection disease
- Dentist
- Gynecologist
- Urologist
- Psychiatrist
- Nutritional Evaluation.
| **23. Primary Ciliary Dyskinesia (PCD)** | **Referral for inclusión by:**
- Pediatric age:
  - Pediatric pneumologist
  - Pediatric
  - Genetist
  - Immunologist
- Adult:
  - Pneumologist
  - Primary care physician (PCP0)
  **PLUS**, one of the following:
  a. Biopsy of ciliated tissue (usually from the nose or trachea) with analysis of ciliary ultrastructure.
  Or
  b. Genetic test showing two mutations known to cause PCD—one from each parent |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Effectiveness</strong></td>
<td>From the date of the diagnosis by one of the specialists listed in the left column or date the biopsy was performed and reported as positive for PCD</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td>Special cover will be in effect as long as the insured is eligible in the PSG</td>
</tr>
</tbody>
</table>

| **1.** All hospital services, emergency room or medical specialist services provided with primary diagnosis of PCD |
| **2.** All medical services provided or ordered by the Neumologist, pediatric or adult, included all referral for evaluation with specialist and subspecialist for conditions related to the primary diagnosis of PCD or its complications. |
| **3.** Medication prescribed by the Neumologist and specific to treat the condition or its complications or medications prescribed by one of the specialist or subspecialists treating or evaluating patients with primary diagnosis of PCD and or its complications. |

| Insurer: Medical services and medications as defined for the special coverage condition in this document and described in the clinical protocol for PCD |
| **GMP/PCP:** Will receive the monthly capitation corresponding to the insured. |

**ICD 10 Codes:**
- Q34.8
- Q34.9
- Q89.3
<table>
<thead>
<tr>
<th>24. Cleft palate and or Cleft lips</th>
<th>a. Usually identified at birth, with physical examination, or prenatal with ultrasound. No need for special test for diagnosis. May be certified by obstetrician or neonatologist/ perinatologist and or pediatrician.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effectiveness: Since diagnosis usually at birth or prenatal. Duration: Until condition is surgically repaired and or age 12. Then and only in those persons requiring further surgeries o management, will be re-certified for 5 years up to two times by ENT, Plastic surgeon or maxillofacial surgeon, with a step-by-step plan for pending surgeries. All visits, evaluations, surgeries, therapies, and rehabilitation. 1. Surgeons who specialize in cleft repair, such as plastic surgeons and 2. Otolaryngologist 3. Oral surgeons 4. Pediatricians 5. Dentists pediatric 6. Orthodontists 7. Nurses 8. Audiologists 9. Speech therapists. 10. Geneticist and/or genetic counselors 11. Social workers 12. Psychologists Laboratories, radiological and nuclear studies Materials and equipment including headphones and/or audiological. Equipment. Required audiological studies Genetic studies Videonasopharyngoscopy nasometry Videofluoroscopy Bone implant or inserts In the special condition protocol, the coverage of evaluations, services, laboratories and other radiological tests and others, will be limited to those that are covered by the Health Plan of the Government of Puerto Rico.</td>
<td></td>
</tr>
<tr>
<td>Insurer: All risk to insurer GMP/PCP: No risk and continues to receive PPMM.</td>
<td></td>
</tr>
</tbody>
</table>
Under no circumstances is it intended to include services, tests, laboratories, or evaluations that are not in the current coverage of the Health Plan of the Government of Puerto Rico.
### 25. IBD (Inflammatory Bowel Diseases)

- Enfermedad de Crohn
- Colitis ulcerativa
- Colitis microscópica

**Crohn’s disease:** ICD-10

- K50.xxx
- K50.0 small bowel
- K50.1 colon
- K50.8 small and large bowel
- K50.9 unspecified

**Ulcerative colitis:** ICD-10

- K51.xxx
- K51.0 pancolitis
- K51.2 proctitis
- K51.3 rectosigmoiditis
- K51.5 left sided colitis
- K51.9 unspecified

**Indeterminate colitis**

- K52.3

---

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
</table>
| 1. A diagnostic certification by a gastroenterologist will be required **AND** | **Effectiveness:** The inclusion as a special condition will be effective from the time the certification is submitted with the associated tests and the definitive diagnosis, according to the inclusion criteria outlined above. **Duration:** The special coverage will last as long as the patient remains subscribed to the PR Government Health Plan. | 1. All hospital, emergency or specialist medical services provided for management once the IBD condition has been diagnosed.  
2. All medical services rendered or ordered by the gastroenterologist or rendered by another specialist referred by the gastroenterologist to evaluate or diagnose and/or treat related conditions or complications of IBD. Special mention is made without being exclusive of: Ophthalmology, surgery, dermatology, rheumatology, infectiology, radiological and imaging services, pathology, nutrition and dietetics, psychiatry, and psychology.  
3. Including all surgeries related to the management, treatment, and complications of IBD.  
4. Medications prescribed by gastroenterologist and specific to treat the condition and its symptoms and complications, including topical therapies, immunomodulators, | 1. Insurer: Medical services and medications as defined for the special coverage condition in this document. | 1. GMP/PCP – will receive the monthly capitation corresponding to the insured. |
biologics, small molecules, and antibiotics, validated by evidence and medical practice.
5. Laboratory tests.
6. All supply and materials for ostomized patients secondary to complication or required appropriate management of IBD, including the following codes:
A4361 OST FACEPLATE
A4362 SKIN BARRIER; SOLID 4 FOUR OR EQUIVALENT; EACH
A4364 ADHESIVE LIQUID OR EQUAL, ANY TYPE PER OZ.
A4367 OST BELT EACH
A4369 OST SKIN BARRIER LIQUID PER OZ
A4371 OST SKIN BARRIER POWDER PER OZ
A4385 OST SKIN BARRIER SOLID 4X4 EXT W/O CONVXITY EA
A4395 OST DEODORANT TO USE IN OSTOMY POUCH SOLID PER TABLET
A4405 OST SKIN BARRIER, NON PECTIN BASED, PASTE PER OZ.
A4406 OST SKIN BARRIER PECTIN-BASED PASTE PER OUNCE
A4407 OST SKIN BARRIER W/BUILT-IN CONVXITY 4X4 IN/< EA
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A4409</td>
<td>OST SKN BARR EXT W/O BUILT-IN CONVXTY 4X4 IN/4X4 IN EA</td>
</tr>
<tr>
<td>A4419</td>
<td>OST POUCH CLOS; BARRIER W/NON-LOCK FLNGE W/FLTR</td>
</tr>
<tr>
<td>A4421</td>
<td>OSTOMY SUPPLY MISCELNEOUS</td>
</tr>
<tr>
<td>A4422</td>
<td>OST ABSORBENT MATERIAL (SHEET/PAD/CRYSTAL PACKET) FOR USE IN OSTOMY POUCH TO THICKEN LIQUID STOMAL OUTPUT, EACH.</td>
</tr>
<tr>
<td>A4450</td>
<td>TAPE NON-WATERPROOF PER 18 SQUARE INCHES</td>
</tr>
<tr>
<td>A4452</td>
<td>TAPE WATERPROOF PER 18 SQUARE INCHES</td>
</tr>
<tr>
<td>A4456</td>
<td>ADHESIVE REMOVER WIPES ANY TYPE EACHA</td>
</tr>
<tr>
<td>A5120</td>
<td>SKIN BARRIER WIPES OR SWABS EACH</td>
</tr>
</tbody>
</table>

The previous list is not exhaustive as it may include some not listed above medical needed supply. Quantity of each supply is according to MCS recommended for each ostomy material or supply.
26. Oculocutaneous albinism, Hermansky-Pudlak syndrome (HSP), and Chédiak-Higashi syndrome (CHS).

**ICD 10 Codes:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E70.329</td>
<td>Oculocutaneous albinism</td>
</tr>
<tr>
<td>E70.331</td>
<td>Hermansky-Pudlak syndrome</td>
</tr>
<tr>
<td>E70.330</td>
<td>Chédiak-Higashi syndrome</td>
</tr>
</tbody>
</table>

A diagnostic certification by one of the following specialists will be required:

- Dermatologist
- Ophthalmologist
- Geneticist

Results of examinations or tests that support the diagnosis such as:

- Genetic testing
- Skin pigments
- Ophthalmological studies

In the case of syndromic OCA, it must also be accompanied by a certification by a hematologist.

**Effectiveness:** Inclusion as a special condition will be effective from the moment the certification is submitted with the associated tests and the definitive diagnosis, according to the inclusion criteria outlined above.

**Duration:** The special coverage will last as long as the patient remains subscribed to the PR Government Health Plan.

1. All medically necessary follow-up services, tests, and procedures by an ophthalmologist or dermatologist for the management of the condition once the diagnosis has been established.

2. In the cases of Hermansky-Pudlak and Chédiak-Higashi Syndrome, the services, tests and procedures offered by a hematologist will also be covered.

3. Medications prescribed by: ophthalmologists, dermatologists and in the cases of Hermansky-Pudlak Syndrome, those prescribed by hematologists, pulmonologists to treat conditions or complications in the management and prevention of complications in this population.

4. Lenses and spectacles specially prescribed for protection, prevention and improvement of vision, according to the quantity and cost parameters of these established by the Vital Plan.

   It is understood that this must include at least prescription glasses every two years or when significant vision changes occur, up to a maximum cost per eyeglass that will not exceed $400.00 per unit.

5. Specific sun protection creams to

**Insurer:** Medical services and medications as defined for the special condition, as well as diagnostic tests, laboratories and other studies required and ordered by the specialist dermatologist, ophthalmologist, geneticist and/or hematologist.

**GMP/PCP:** Will receive the monthly capitation corresponding to the insured.
| prevent complications from exposure to ultraviolet rays. These lotions or creams must offer an SPF sun protection factor of 50 or more and protect against ultraviolet A and B (UVA and UVB) rays. The recommendation is about 24 ounces per month (three (3) 8 oz. bottles/month). |